Fanconi syndrome and renal failure induced by tenofovir: a first case report.
Although nephrotoxicity of cidofovir and adefovir is well established, no renal side effects have been observed yet with tenofovir, which is the third member of this family. The authors report the case of a patient who had Fanconi syndrome, nephrogenic diabetes insipidus, and acute renal failure during treatment with tenofovir, a nucleotide reverse transcriptase inhibitor that recently has been approved by the Food and Drug Administration for treatment of patients infected with human immunodeficiency virus.
Verhelst
David
D
Department of Nephrology, Hôpital Tenon (AP-HP), Paris, France. verhelsttenon@yahoo.fr
Monge
Matthieu
M
Meynard
Jean-Luc
JL
Fouqueray
Bruno
B
Mougenot
Béatrice
B
Girard
Pierre-Marie
PM
Ronco
Pierre
P
Rossert
Jerome
J
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D005198:Fanconi Syndrome / Q000139:chemically induced*; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D000068698:Tenofovir; D000225:Adenine